Literature DB >> 29248381

High-grade thalamic gliomas: Microsurgical treatment and prognosis analysis.

Biwu Wu1, Chao Tang2, Yang Wang2, Zhiqi Li2, Shukun Hu2, Wei Hua2, Wengang Li1, Shan Huang1, Junfeng Ma1, Yi Zhang3.   

Abstract

This retrospective study is aimed to investigate the efficacy of microsurgical treatment for high-grade thalamic gliomas, and to analyze the relevant prognosis. From May 2011 to Aug 2015, 49 patients with thalamic gliomas underwent microsurgical resection, and received chemotherapy and radiotherapy postoperatively. The postoperative symptoms and complications were documented, and the overall survival (OS) and the progression-free survival (PFS) data were collected. The prognostic factors were evaluated by univariate and multivariate analyses. Finally, there was no perioperative death. Twenty cases, 24 cases and 5 cases were achieved subtotal resection (>90%), partial resection (70-90%) and less than partial resection (<70%) respectively. All patients' pathological diagnosis was confirmed. The symptoms were improved in 32 cases, unchanged in 11 cases, and worsen in 6 cases. Postoperative complications were absent in 9 cases. The 6-month, 12-month, and 24-month OS were 71.4%, 38.9%, and 12.1% respectively; corresponding PFS were 66.6%, 27.1%, and 10.2% respectively. The median OS time and PFS time were 9.0 months (95% CI 6.9-11.1) and 9.0 months (95% CI 6.6-11.4) respectively. Multivariate analysis revealed extent of resection were independent prognostic factors for OS (p < .05), patients with postoperative adjuvant chemotherapy and radiotherapy had a significant prolonged OS (p < .001) and PFS (p < .001). The study shows that the short-term efficacy of microsurgery for high-grade thalamic gliomas is satisfactory. Microsurgery can effectively alleviate patients' symptoms and improve life quality. Postoperative adjuvant chemotherapy and radiotherapy are helpful for prolonging the survival time.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Microsurgical treatment; Prognosis; Thalamic gliomas

Mesh:

Year:  2017        PMID: 29248381     DOI: 10.1016/j.jocn.2017.12.008

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  In Reply: Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.

Authors:  Yoshua Esquenazi; Nelson Moss; Viviane Tabar
Journal:  Neurosurgery       Date:  2019-05-01       Impact factor: 4.654

2.  Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.

Authors:  Xiaodong Niu; Tianwei Wang; Xingwang Zhou; Yuan Yang; Xiang Wang; Haodongfang Zhang; Ni Chen; Qiang Yue; Feng Wang; Yuekang Zhang; Yanhui Liu; Qing Mao
Journal:  J Neurooncol       Date:  2020-03-10       Impact factor: 4.130

3.  Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma.

Authors:  Jaejoon Lim; YoungJoon Park; Ju Won Ahn; So Jung Hwang; Hyouksang Kwon; Kyoung Su Sung; Kyunggi Cho
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

4.  Risk Factors for Early Hydrocephalus on Post Unilateral Thalamic Tumor Resection.

Authors:  Linpeng Zhang; Chen Wang; Xianwei Zeng
Journal:  Front Surg       Date:  2022-04-08

5.  H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients.

Authors:  Xiao Mu Hu; Xiao Yu Nie; Kai Lun Xu; Yin Wang; Feng Tang; Zun Guo Du; Ji Xiong
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

6.  H3 K27M-mutant glioma: clinical characteristics and outcomes.

Authors:  Tianwei Wang; Yongming Qiu; Lili Liang; Erliang Zheng; Ting Gao
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.